Elevated Lipoprotein(a) and Cardiovascular Outcomes After Percutaneous Coronary Intervention: A Systematic Review

Mohamed A Alshibane1, Mohamed Abdelrahman Mohamed Ali2, Mohamed Ahmed3

  • 1Biomedical Sciences, University of Reading, Reading, GBR.

Cureus
|April 29, 2026
PubMed

Insights

Elevated Lipoprotein(a) (Lp(a)) significantly increases cardiovascular risks after percutaneous coronary intervention (PCI). Aggressive low-density lipoprotein cholesterol (LDL-C) lowering may reduce this risk, suggesting routine Lp(a) measurement for better risk stratification in PCI patients.

Area of Science:

  • Cardiovascular Medicine
  • Interventional Cardiology
  • Lipidology

Background:

  • Lipoprotein(a) (Lp(a)) is a genetically determined lipoprotein linked to atherosclerosis and thrombosis.
  • The prognostic significance of elevated Lp(a) in patients undergoing percutaneous coronary intervention (PCI) requires further elucidation.

Purpose of the Study:

  • To systematically review and evaluate the association between elevated Lp(a) levels and cardiovascular outcomes following PCI.

Main Methods:

  • A comprehensive literature search was performed across major databases (PubMed, Embase, Scopus, IEEE Xplore, Web of Science) for studies published between 2021 and 2025.
  • Included were observational studies assessing Lp(a) and cardiovascular outcomes in PCI patients, with quality assessed by the Newcastle-Ottawa Scale (NOS).
  • Eight studies involving 23,421 patients were analyzed, with Lp(a) thresholds varying from ≥30 mg/dL to ≥50 mg/dL.

Main Results:

  • Seven of eight studies found a significant positive association between elevated Lp(a) and adverse cardiovascular events (MACEs), with hazard ratios ranging from 1.14 to 4.29.
  • Elevated Lp(a) correlated with increased risks of myocardial infarction, stent thrombosis, and repeat revascularization.
  • The prognostic impact of Lp(a) was most significant in high-risk patients and those with diabetes; aggressive low-density lipoprotein cholesterol (LDL-C) lowering may attenuate this risk.

Conclusions:

  • Elevated Lp(a) is an independent predictor of adverse cardiovascular outcomes post-PCI.
  • Routine Lp(a) measurement could aid in risk stratification and secondary prevention strategies for PCI patients.
  • Further prospective and interventional studies are necessary to confirm these findings and guide clinical practice.

Related Concept Videos

Coronary Artery Disease I: Introduction01:30

Coronary Artery Disease I: Introduction

Coronary Artery Disease (CAD): An Overview with Scientific InsightsCoronary Artery Disease (CAD), often referred to as C-A-D, is a prevalent blood vessel disorder classified under the broader category of atherosclerosis. Atherosclerosis is a pathological process characterized by the hardening and narrowing of arteries due to the accumulation of atherosclerotic plaques. These plaques are composed of cholesterol, fatty substances, inflammatory cells, calcium, and fibrin, reducing blood flow to...
1.8K
Coronary Artery Disease IV: Preventive Measures01:26

Coronary Artery Disease IV: Preventive Measures

Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...
890
Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
444
Atherosclerosis I: Introduction01:30

Atherosclerosis I: Introduction

Atherosclerosis is a progressive disorder characterized by the buildup of plaques on the arterial inner wall, causing them to narrow and harden over time. These plaques comprise lipids, calcium, blood components, carbohydrates, and fibrous tissue. The process primarily affects the intima of large and medium-sized arteries, reducing blood flow in any artery.Etiology and risk factorsThe cause of atherosclerosis is multifactorial, involving a complex interplay among endothelial injury, lipid...
2.5K
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
741
Peripheral Artery Disease III: Interprofessional Care01:27

Peripheral Artery Disease III: Interprofessional Care

Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...
655